HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer data

HUTCHMED said on September 24, 2026 that results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations, with the global SAFFRON study featured in the Presidential Symposium session and the SANOVO study in China presented in a Proffered Paper session¹ at the ESMO Congress, which the company noted takes place October 23-27, 2026, in Madrid, Spain¹.

The SAFFRON study looked at the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib¹. The company said the trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) compared to doublet platinum-based chemotherapy¹.

SANOVO tested the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression¹. HUTCHMED said the trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy¹.

Per the abstract listings, the SAFFRON presentation is led by Shun Lu and scheduled for Sunday, October 25, 2026, in Presidential Symposium II¹, while SANOVO is led by Yi-Long Wu and scheduled for Monday, October 26, 2026, in a Proffered paper session on metastatic NSCLC¹. The company said having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer¹.